Clinical trials: Pancreatic Acinar Carcinoma, open to volunteers
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Patients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all.
- Trial name
- VAPOR (NCT05727020)
- Testing
- Breath test, Collection of matched samples of breath, biofluids and pancreatic tissue
- Where
- United Kingdom
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pancreas Cancer, Pancreatitis
Pancreas Registry and High Risk Registry
The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of…
- Conditions
- Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst
- Trial name
- NCT02775461
- Where
- 2 sites in United States
- Volunteers
- 1,368 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pancreatic Cancer Metastatic
Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions
1. Study: A Clinical Study of Intra-cavity Adebrelimab Combined with Best Supportive Care for Pancreatic Cancer Patients with Pleural or Peritoneal Effusion (Malignant Ascites) 2.
- Trial name
- NCT07230301
- Testing
- Adebrelimab (PD-L1 inhibitor)
- Volunteers
- 20 people
- Sponsor
- Sizhen Wang
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and…
- Trial name
- NCT06761027
- Testing
- Anlotinib combined with Sintilimab
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Fujian Provincial Hospital
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Non-Resectable Pancreas Carcinoma
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
A randomized, multicenter, Phase III trial evaluating the efficacy and safety of first-line Sequential AG-mFOLFOX chemotherapy combined with Serplulimab and Bevacizumab versus AG chemotherapy alone in advanced pancreatic cancer.
- Trial name
- NCT07235930
- Testing
- Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab, AG chemotherapy
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Zhejiang Cancer Hospital
Pancreas Cancer, Diabetes
Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer Surgery
The primary aim of the present study is to examine the effect of a "structured follow-up intervention" to be performed in the first three months after PD on blood glucose.
- Trial name
- FiGluR (NCT06774170)
- Testing
- structured follow-up intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Dokuz Eylul University
Pancreatic Fluid Collections, Biliary Obstruction
EUS Procedures Using RIVOS™ EUS Access Device
This is a prospective study of patients undergoing EUS procedures using the RIVOS™ EUS access device.
- Conditions
- Pancreatic Fluid Collections, Biliary Obstruction, Pancreatic Duct Obstruction, Chronic Pancreatitis
- Trial name
- NCT07696572
- Testing
- EUS-guided intervention using the RIVOS™ EUS access device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Orlando Health, Inc.
Biliary Stricture, Bile Duct Cancer
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
Biliary stricture is mainly malignant in the adults and caused by several types of fatal malignancies such as pancreatic cancer, cholangiocarcinoma, and metastatic tumor, which have poor prognosis that the overall survival of…
- Conditions
- Biliary Stricture, Bile Duct Cancer, Pancreas Cancer
- Trial name
- ECCBILE (NCT06277531)
- Where
- 2 sites in China
- Volunteers
- 99 people
- Sponsor
- Peking University Third Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer Metastatic
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
This is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients.
- Trial name
- NCT07920731
- Testing
- imotuzumab combined with the NALIRIFOX chemotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Advanced Gastric and Pancreatic Cancer
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
The goal of this clinical trial is to learn if CBG131 works to treat advanced gastric cancer or pancreatic cancer in adults whose tumors are CLDN18.2-positive.
- Trial name
- NCT07394205
- Testing
- CBG131 CAR-T Cell Infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Pancreatic Cancer
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
In this prospective study, new diagnostic tools will be explored for patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant chemotherapy with FOLFIRINOX.
- Trial name
- PeRFormanCe (NCT05298722)
- Testing
- Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.
- Where
- 8 sites in Belgium, Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
First-line Treatment of Metastatic Pancreatic Cancer
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus…
- Trial name
- NCT07238283
- Testing
- Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 662 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreas Cancer, Lung Cancer
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies.
- Conditions
- Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
- Trial name
- NCT06196294
- Testing
- Cell therapy for solid tumors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
A IIT Study of 177Lu-DOTA-SNA040
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced…
- Conditions
- Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction), Advanced Solid Tumors (Such as Pancreatic Cancer), Advanced Solid Tumors (Such as Cholangiocarcinoma)
- Trial name
- NCT07595237
- Testing
- 177Lu-DOTA-SNA040
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
Pancreatic Cancer, Surgery
Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.
The IMPULS trial is a randomized, triple-blinded, placebo controlled, single center, pilot trial examining the efficacy and safety of preoperative propranolol in patients scheduled for pancreatic cancer surgery.
- Trial name
- IMPULS (NCT06145074)
- Testing
- Propranolol
- Where
- 2 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- Zealand University Hospital
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer
The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer
- Trial name
- NCT07132060
- Testing
- MR-guided Irradiation
- Volunteers
- 30 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.